Evidence map›Paper›PMID 35662803›Full record

ArticleOphthalmology science2022

Machine learning OCT predictors of progression from intermediate age-related macular degeneration to geographic atrophy and vision loss.

Eleonora Lad, Karim Sleiman, David L Banks, Sanjay Hariharan, Traci Clemons, Rolf Herrmann, Daniyar Dauletbekov, Andrea Giani, Victor Chong, Emily Y Chew and 1 more

Open access · goldAbstract read
In one paragraph

Article in Ophthalmology science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 4 countries.

Eleonora LadDepartment of Ophthalmology, Duke University Medical Center, Durham, NC, USA.
Karim SleimanDepartment of Ophthalmology, Duke University Medical Center, Durham, NC, USA.
David L BanksDepartment of Statistical Science, Duke University, Durham, NC, USA.
Sanjay HariharanDepartment of Statistical Science, Duke University, Durham, NC, USA.
Traci ClemonsThe Emmes Corporation, Rockville, MD, USA.
Rolf HerrmannBoehringer Ingelheim International GmBH, Ingelheim am Rhein, Germany.
Daniyar DauletbekovBoehringer Ingelheim International GmBH, Ingelheim am Rhein, Germany.
Andrea GianiBoehringer Ingelheim International GmBH, Ingelheim am Rhein, Germany.
Victor ChongBoehringer Ingelheim International GmBH, Ingelheim am Rhein, Germany.
Emily Y ChewNational Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Cynthia A TothDepartment of Ophthalmology, Duke University Medical Center, Durham, NC, USA.
Eye Center · SABoehringer Ingelheim (Germany) · DEDuke University · USEmory Eye Center · USDuke Medical Center · USNational Eye Institute · USNational Institutes of Health · USAlkermes (Ireland) · IEEmmes (United States) · US

Funding

Intraoperative OCT Guidance of Intraocular SurgeryR01EY023039 · NEI · DUKE UNIVERSITY · PI IZATT, JOSEPH A, TOTH, CYNTHIA ANN · 2013 to 2016
$3.9M
Age-Related Eye Disease Follow-up Study (AREDS) Follow-up StudyZIAEY000489 · NEI · NATIONAL EYE INSTITUTE · PI CHEW, EMILY Y · 2009 to 2025
$639k
Monocytes in Dry Age-Related Macular DegenerationK23EY026988 · NEI · DUKE UNIVERSITY · PI LAD, ELEONORA GEORGETA · 2016 to 2018
$420k
Role of Macrophages in Age-Related Macular DegenerationI01CX002116 · VA · DURHAM VA MEDICAL CENTER · PI LAD, ELEONORA GEORGETA · 2020 to 2023
–
CSRD VA I01 CX002116NEI NIH HHS K23 EY026988NEI NIH HHS R01 EY023039
6 · The paper itself

Abstract

Objective: To describe optical coherence tomography (SD-OCT) features, age, gender, and systemic variables that may be used in machine/deep learning studies to identify high-risk patient subpopulations with high risk of progression to geographic atrophy (GA) and visual acuity (VA) loss in the short term. Design: prospective, longitudinal study. Subjects: We analyzed imaging data from patients with iAMD (N= 316) enrolled in Age-Related Eye Disease Study 2 (AREDS2) Ancillary SD-OCT with adequate SD-OCT imaging for repeated measures. Methods: Qualitative and quantitative multimodal variables from the database were derived at each yearly visit over 5 years. Based on statistical analyses developed in the field of cardiology, an algorithm was developed and used to select person-years without GA on colour fundus photography or SD-OCT at baseline. The analysis employed machine learning approaches to generate classification trees. Eyes were stratified as low, average, above average and high risk in 1 or 2 years, based on OCT and demographic features by the risk of GA development or decreased VA by 5+ and 10+ letters. Main outcome measures: new onset of SD-OCT-determined GA and VA loss. Results: We identified multiple retinal and subretinal SD-OCT and demographic features from the baseline visit, each of which independently conveyed low to high risk of new-onset GA or VA loss on each of the follow-up visits at 1 or 2 years. Conclusion: We propose a risk-stratified classification of iAMD based on the combination of OCT-derived retinal features, age, gender and systemic variables for progression to OCT-determined GA and/or VA loss. After external validation, the composite early endpoints may be used as exclusion or inclusion criteria for future clinical studies of iAMD focused on prevention of GA progression or VA loss.

Indexed as

classification treesgeographic atrophyMachine learningpredictionrandom forest

Identifiers

PMID35662803
PMCPMC9161427
OpenAlexW4224212640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.